Magnetic resonance imaging for phenotyping and accurate Monitoring of Interstitial Lung Disease: the M-ILD study
- Conditions
- Interstitiele longziekten (Interstitial Lung Disease, ILD)Interstitial lung diseases (ILD)lung diseases
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 60
- Multidisciplinary diagnosis of PF-ILD (progressive fibrotic ILD group
including IPF) OR inflammatory ILD (including idiopathic NSIP, ILD related to
connective tissue disease or with autoimmune features or chronic
hypersensitivity pneumonitis (IGr).
- Informed consent
- About to start treatment for their ILD. Each patient will be treated as
decided in the MDT according to standard clinical practice. PF-ILD and IPF
group are usually treated with anti-fibrotic drugs (nintedanib or pirfenidone).
The I-ILD group are treated with anti-inflammatory therapy, such as prednisone,
mycophenolate mofetil, azathioprine, rituximab.
Additional inclusion criteria for subgroup of ILD patients who undergo FDG
PET-MRI:
PF-ILD group:
- Patients of PF-ILD group with sign of disease activity as indicated by PFT
and symptoms (dyspnea, exercise capacity, cough)
I-ILD group:
- Patients of I-ILD group with sign of disease activity as indicated by and
symptoms (dyspnea, exercise capacity, cough)
- Contra-indications or inability to undergo MRI (i.e. claustrophobia.)
- Current lung infection (according to treating physician)
- Respiratory distress at rest despite oxygen
- Contra-indication to use gadolinium contrast (severe renal insufficiency,
estimated glomerular filtration rate [eGFR] <30 mL/min per 1.73 m2)(28)
- Previous allergic reaction to gadolinium or iodinated contrast media
- Acute ILD exacerbations at baseline
- High flow chronic oxygen need(respiratory distress at rest despite oxygen)
- Lung cancer at baseline
- For PF-ILD group: previous treatment with anti-fibrotic medications
- For I-ILD group: previous treatment with anti-inflammatory medications
Additional exclusion criteria for subgroup of ILD patients who undergo FDG
PET-MRI:
PF-ILD group:
- Ongoing treatment with anti-fibrotic modulators at baseline
I-ILD group:
- Ongoing treatment with anti-inflammatory and/or immunomodulators at baseline
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Amount of fibrotic and inflammatory lung on chest CT and chest MRI. Response to<br /><br>treatment according to pulmonary function test (PFT) change.</p><br>
- Secondary Outcome Measures
Name Time Method <p>- To correlate CT and MRI findings with ILD blood biomarkers and lung function<br />test<br />- To assess whether photon counting chest CT (photon counting CT) is superior<br />to standard CT in terms of resolution, dose reduction and quantification of<br />lung fibrosis</p>